Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Swedish Orphan Biovitrum AB ( (SE:SOBI) ).
Shareholders in Swedish Orphan Biovitrum approved all board proposals at the company’s annual general meeting, including the adoption of the 2025 accounts and the decision to carry forward retained earnings, while granting discharge of liability to directors and the chief executive. The meeting re-elected several board members, added Mikael Dolsten and Åsa Riisberg, confirmed David Meek as chair, and renewed Ernst & Young as auditor, reinforcing continuity in governance.
The AGM backed new and existing long-term incentive programmes, authorising a directed issue and repurchase of series C shares for an all-employee plan and an equity swap to hedge a management scheme. Shareholders also granted the board a broad mandate to issue up to 39.71 million new shares, convertibles or warrants and approved the transfer of treasury shares to cover costs of incentive plans from 2021–2023, giving Sobi financial and capital-structure flexibility to support future growth initiatives.
The most recent analyst rating on (SE:SOBI) stock is a Buy with a SEK350.00 price target. To see the full list of analyst forecasts on Swedish Orphan Biovitrum AB stock, see the SE:SOBI Stock Forecast page.
More about Swedish Orphan Biovitrum AB
Swedish Orphan Biovitrum AB (Sobi) is a global biopharmaceutical company focused on breakthrough treatments for rare diseases. The Stockholm-listed group employs about 2,000 people across Europe, North America, the Middle East, Asia and Australia, and generated revenue of SEK 28 billion in 2025.
Average Trading Volume: 436,941
Technical Sentiment Signal: Buy
Current Market Cap: SEK148.9B
Find detailed analytics on SOBI stock on TipRanks’ Stock Analysis page.